What is the best probiotic for you?
Clostridium difficile is a bacterium that normally lives in the intestines of about 5% of the population without causing any issues(1). However, after antibiotic treatment, the balance of intestinal bacteria may be disrupted, allowing C. difficile to grow and potentially cause an infection(3). Once established, the bacteria produce toxins that can damage the intestines and lead to diarrhea(2).
Clostridium difficile-associated diarrhea (CDAD) is the leading cause of hospital-acquired infectious diarrhea.
Common symptoms of a C. difficile infection:
-
Diarrhea
-
Abdominal cramps
-
Fever
Most people affected recover with antibiotic treatment, although research estimates that initial treatment fails in over 20% of patients infected by this bacterium(4). Some more vulnerable individuals may experience serious complications, such as significant inflammation of the intestines or severe dehydration(2).
Blood, mucus, or pus may also be present in the stool.
People undergoing antibiotic therapy are 7 to 10 times more likely to develop the infection(5). Individuals in hospital settings or long-term care facilities are also considered at-risk populations(6).
Studies regarding Probaclac Medic
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial
Administration of Probaclac probiotics as a preventive measure to prevent the spread of C. difficile infections has been shown to be effective.(6).
he Santa Cabrini Hospital in Montreal administered Probaclac Adult Formula probiotics to all patients receiving antibiotic treatment in an effort to control the spread of the infection.
Conducted over a period of 8 months and involving 5,000 individuals, the study was double-blind and carried out entirely independently of Laboratoires Nicar (9).
Following the probiotic therapy, CDAD cases decreased among the hospital’s patients.
Administering Probaclac probiotics as a preventive measure to stop the spread of C. difficile infections proved to be effective.
-
Broad-spectrum antibiotics act against a wide range of bacteria to fight infections.
They are a powerful weapon that must be used with caution, as they target bacteria without distinguishing between the harmful pathogens causing the infection and the beneficial bacteria residing in the gut microbiota. They are the perfect example of a medical double-edged sword(8).
The resulting disruption of the intestinal bacterial balance can lead to antibiotic-associated diarrhea (AAD).
PROBACLAC MEDIC AND THE BENEFITS OF SACCHAROMYCES BOULARDII YEAST
Several studies have confirmed the effectiveness of the probiotic yeast Saccharomyces boulardii, also known as S. boulardii, in the preventive treatment of this unfortunate consequence of antibiotic therapy.
This probiotic is not affected by antibiotics and helps restore the gut microbiota to prevent unpleasant intestinal disturbances(9).
A randomized, double-blind, controlled study involving 151 hospitalized adult patients demonstrated the probiotic’s effectiveness.
The placebo group developed diarrhea at a rate of 9%, while the supplemented group had a rate of only 1.4% — a 7.6% decrease(10).
The beneficial effect of the probiotic was also reproduced in a randomized, double-blind, controlled trial involving 269 children aged between 6 months and 14 years1).
Probaclac Medic contains 5 billion active cells per capsule, the same dosage administered to the experimental group in the adult population study.
Studies regarding Probaclac Medic
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial
Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study
PROBACLAC GI AND THE BENEFITS OF THE LACTOBACILLUS RHAMNOSUS STRAIN
Recommended to prevent antibiotic-associated diarrhea.
Lactobacillus rhamnosus GG significantly reduces the risk of developing diarrhea related to antibiotic use(13-19).
Oral Bacterial Therapy Reduces the Duration of Symptoms and of Viral Excretion in Children with Mild Diarrhea
Probiotics for treatment of acute diarrhea in children: randomized clinical trial of five different preparations
Oral Bacterial Therapy Reduces the Duration of Symptoms and of Viral Excretion in Children with Mild Diarrhea
Infectious diarrhea is a form of acute diarrhea. The WHO defines it as the passage of at least three loose or liquid stools per day for less than two weeks. The causes fall into three categories: viruses, bacteria, and parasites.
Studies suggest that disrupted gut balance can be restored through rehydration and probiotic supplementation.
Lactobacillus rhamnosus GG is a well-documented probiotic strain that has shown numerous benefits for digestive and immune health in several clinical studies.
Lactobacillus rhamnosus GG has been clinically shown to promote the growth of friendly bacteria essential for maintaining a healthy balance in the intestinal microbiota(3-10).
The GG strain naturally has the ability to survive gastric acidity and act as a barrier against the development of harmful intestinal pathogens(1-2).
Clinical data on GG have demonstrated, among other things, its ability to reduce both the incidence and duration of diarrhea episodes caused by viral or bacterial infections(4-5).
(4-5).
The beneficial effect of the probiotic was also replicated in a randomized, double-blind, controlled trial involving 269 children aged between 6 months and 14 years.
The Probaclac Medic formula contains 5 billion active cells per capsule, the same amount that was administered to the experimental group in the study conducted on the adult population.
he formula contains 8 billion bacteria of 3 different strains and helps to regulate the Döderlein flora by repopulating it.
The effectiveness of Probaclac vaginal probiotics in reducing the recurrence of bacterial vaginosis has been scientifically proven.
The formula contains 8 billion bacteria of 3 different strains and helps to regulate the Döderlein flora by repopulating it.
A study was conducted among 120 women with a history of recurrent bacterial vaginosis.
The results are conclusive and demonstrate that the insertion of probiotics into the vaginal cavity reduces the recurrence of bacterial vaginosis by more than 80%(18).
Bacterial Vaginosis
The vaginal flora is composed of microorganisms, including a very large quantity of lactobacilli bacteria, called the Döderlein flora, which represents approximately 95% of the vaginal ecosystem(12).
Döderlein's good bacteria form a protective biofilm on the vaginal mucosa(13).
The protective effect of lactobacilli is declined in different mechanism of action. Among other things, they inhibit the growth of pathogenic bacteria by secreting a variety of substances and impair their adhesion to vaginal epithelial cells by filling the surface(14).
Although the Döderlein flora is a suitable protection, it is not foolproof and it is possible that an imbalance of the vaginal microbiota occurs.
The balance can be disturbed with a decrease in good bacteria, a proliferation of bad bacteria or yeasts(13).
Various causes can lead to this imbalance :
-
periods of hormonal variations such as pregnancy
-
external factors such as antibiotic therapy
-
excessive vaginal hygiene
-
sexual intercourse
-
stress
-
tobacco(15).
Bacterial vaginosis is a disequilibrium that can be caused by the proliferation of a number of bacteria, including Gardnerella vaginalis or Prevotella, which are normally found in the sub-dominant vaginal flora(14).
This change in the ecosystem involves an increase of the normally acidic vaginal pH and thus an infection. This infection is asymptomatic in half of women, however, when symptoms occur they are particularly bothersome for the affected woman(16). Typically, they are characterized by heavy vaginal discharge of a gray/greenish smelly substance(17).
Studies about Probaclac Vaginal
-
All of our probiotics
Probaclac probiotic strains survive without an enteric-coated capsule in a pH of 3
Once consumed probiotics follow the natural path through the digestive tract. Starting in the mouth then traveling through the esophagus probiotics then reach the stomach, a very acidic environment when it is empty. Its acidity level varies according to what it contains, in the fasting stomach the pH is at around 1 and it rises to 6 when it is full.
The alkalization of the stomach when it contains nutrients is the reason why it is better to consume probiotics while eating. The number of active bacteria in the supplements can be affected if it faces a very acidic environment.
In order to ensure product efficacy, probiotic manufacturers must be able to demonstrate that their probiotic strains can withstand a pH3 environment. All strains of Probaclac supplements are able to survive an acid trip and therefore the viability of the bacteria is ensured to the intestines. An enteric-coated capsule is not needed for the bacteria to arrive safely. Not to mention that Lactobacillus strains are normally found in the stomach, the path traveled presents an opportunity to repopulate this flora.
1 Université Laval – Contact [Site web] :Entrevue avec André Marette, Professeur au Département de médecine et Chercheur à l’Institut universitaire de cardiologie et de pneumologie de Québec. Consulté 31 août 2017. http://www.contact.ulaval.ca/article_magazine/la-revanche-de-lintestin/
2 Guarino A, Guandalini S et Lo Vecchio A.Probiotics for Prevention and Treatment of Diarrhea. J Clin Gastroenterol. 2015 Nov-Dec ; 49 Suppl 1 : s37-45.
3 Allen SJ, Wareham K, Wang D et al.A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). Health Technol Assess. 2013 Dec ; 17(57) : 1-140.
4 McFarland LV.Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease. Am J Gastroenterol. 2006 ; 101 : 812-822.
5 Perna S, Barriga P, Sirvent H, Knowles H et al.Important Risk Reduction in Nosocomial Clostridium Difficile with Institution of Probiotic Prophylaxis. Annu Rev Microbiol. 2014 ; 68 : 217-35.
6 Micklefield G. Saccharomycesboulardii in the treatment and prevention of antibiotic-associated diarrhea. MMW Fortschr Med. 2014 Apr; 156 Suppl 1: 18-22.
7 Kotowska M, Albrecht P et Szajewska H. Saccharomycesboulardii in the prevention of antibiotic-associated diarrhoea in children : a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005 Mar ; 21(5) : 583-90.
8 Bischoff, SC.Microbiota and aging. Curr Opin Clin Nutr Metab Care. 2016 Jan ; 19 (1) : 26-30.
9 Rondanelli M, Giocosa A, Faliva MA et al.Review on microbiota and effectiveness of probiotics use in older. World J Clin Cases. 2015 Feb 16 ; (2) : 156-62.
10 Kollaritsch H, Paulke-Korinek M et Wiedermann U.Traveler’s Diarrhea. Infect Dis Clin North Am. 2012 Sep ; 26(3) : 691-706.
11 Hill DR et Beeching NJ.Travelers’ diarrhea. Curr Opin Infect Dis. 2010 Oct ; 23(5) : 481-7.
12 Martinez-Martinez MI, Calabuig-Tolsa R et Cauli O.The effect of probiotics as a treatment for constipation in elderly people : A systematic review. Arch Gerontol Geriatr. 2017 Jul ; 71 : 142-149.
13 Société canadienne de pédiatrie [Document de principes].L’utilisation de probiotiques au sein de la population pédiatrique. 28 février 2015.
14 Brenner DM, Moeller MJ, Chey WD et Schoenfeld PS.The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009 Apr ; 104(4) : 1033-49.
15 Akbari E, Asemi Z, Daneshvar Kakhaki R et al.Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer’s Disease: A Randomized, Double-Blind and Controlled Trial. Front Aging Neurosci. 2016 ; Nov 10 (8) : 26-30.
16 Hanson L, VandeVusse L, Jermé M et al.Probiotics for Treatment and Prevention of Urogenital Infections in Women : A Systematic Review. J Midwifery Womens Health. 2016 ; May (3) : 339-355.
17 Ya W, Reifer C et Miller LE.Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol. 2010 ; Aug (2) : 120.
18 Kovachev S et Dobrevski-Vacheva R.Effect of Lactobacillus casei var rhamnosus (Gynophilus) in restoring the vaginal flora by female patients with bacterial vaginosis– randomized, open clinical trial. Akush Ginekol (Sofiia). 2013 ; 52 Suppl 1 : 48-53.
19 Bischoff, SC.Microbiota and aging. Curr Opin Clin Nutr Metab Care. 2016 ; Jan 19 (1) : 26-30.
20 Naître et Grandir [Site web].Consulté le 10 mai 2017. http://naitreetgrandir.com/fr/etape/1_3_ans/alimentation/fiche.aspx?doc=bg-naitre-grandir-probiotique
21 West CE.Probiotics for allergy prevention. Benef Microbes. 2016 ; 7 (2) : 171-9.
22 Kumar M, Nagpal R, Kumar R, Hemalatha R et al.Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012 May [E-pub].
23 Khalesi S, Sun J, Buys N et Jayasinghe R.Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014 Oct ; 64(4) : 897-903.
24 Kali A.Psychobiotics: An emerging probiotic in psychiatric practice. Biomed J. 2016 Jun; 39(3): 223-4.
25 Savignac HM, Kiely B et al.Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. Neurogastroenterol Motil. 2014 Nov ; 26(11) : 1615-27.
26 Galland L.The gut microbiome and the brain. J Med Food. 2014 Dec ; 17(12) : 1261-72.
27 Dinan TG, Borre YE et Cryan JF.Genomics of schizophrenia : time to consider the gut microbiome? Mol Psychiatry. 2014 Dec ; 19(12) : 1252-7.
28 Society for Neuroscience [2015 Annual Meeting].Abstract 162.04. Présenté le 18 octobre 2015.
29 Dinant TG, Stanton C et Cryan JF.Psychobiotics : a novel class of psychotropic. Biol Psychiatry. 2013 Nov ; 74(10) : 720-6.
30 Fédération québécoise de l’autisme [Site Web].Consulté le 8 juillet 2017. http://www.autisme.qc.ca/tsa/lautisme-en-chiffres.html
31 Li Q et Zhou JM.The microbiota-gut-grain axis and its potential therapeutic role in autism spectrum disorder. Neuroscience. 2016 Jun ; 324 : 131-9.
32 Sanchez M, Darimont C, Drapeau V, Emady-Azar S et al.Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br J Nutr. 2014 Apr ; 111(8) : 1507-19.
33 Mekkes MC, Weenen TC, Brummer RJ et Claassen E.The development of probiotic treatment in obesity : a review. Benef Microbes. 2014 Mar ; 5(1) : 19-28.
34 Sharma D, Kober MM et Bowe WP.Anti-Aging Effects of Probiotics. J Drugs Dermatol. 2016 ; Jan 15 (1) : 9-12.
35 Yates AA, Edman JW, Shao A et al.Bioactive nutrients – Time for tolerable upper intake levels to address safety. Regul Toxicol Pharmacol. 2017 Mar ; 84 : 94-101.
36 Jean-Yves Dionne [Site web].Consulté le 23 juin 2017. http://www.jydionne.com/comment-choisir-un-supplement-de-probiotiques/
37 Van den Nieuwboer M, Brummer RJ, Guarner F et al.The administration of probiotics and synbiotics in immune compromised adults: is it safe? Benef Microbes. 2015 Mar ; 6(1) : 3-17.
38 Association canadienne des aliments de santé [Site web].Consulté 31 août 2017. https://chfa.ca/fr/npn/canadian-npn-explained.html
39 Timmerman HM, Koning CJ, Mulder L, Rombouts FM et Beynen AC.Monostrain, multi strain and multispecies probiotics–A comparison of functionality and efficacy. Int J Food Microbiol. 2004 Nov ; 15 (3) : 219-33.
40 Chapman CM, Gibson R et Rowland I.In vitro evaluation of single- and multi-strain probiotics: Inter- species inhibition between probiotic strains, and inhibition of pathogens. Anaerobe. 2012 Aug ; 18 (4) : 405-413.
41 Santé Canada [Site web].Consulté 5 septembre 2017. http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=probio&lang=fra
42 Flesch AG, Poziomyck AK et Damin DC.The therapeutic use of symbiotics. Are Bras Cir Dig. 2014 Jul-Sep ; 27 (3) : 206-9.